Description
Creative Biolabs enhances the binding ability of the anti-CEACAM8 antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the antibody.
Applications
Increase the half-life of antibodies
Technology
Fc engineering technology
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CEACAM8 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Carcinoembryonic Antigen Related Cell Adhesion Molecule 8
Background
Besilesomab; scintimun; 537694-98-7; BW 250/183; CEACAM8; carcinoembryonic antigen-related cell adhesion molecule 8; CGM6; CD66b; CD67 antigen; carcinoembryonic antigen CGM6; non-specific cross-reacting antigen NCA-95; carcinoembryonic antigen gene family member 6;
Antibody Clone
AES-0622-ZP1268
Description
Creative Biolabs enhances the binding ability of the anti-CEACAM8 antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the anti- antibody.
